In Reply The letter from Pfeffer et al outlines the authors’ rationale for their belief that the AA genotype for the rs1967309 single-nucleotide polymorphism (SNP) in the ADCY9 gene is likely associated with a cardiovascular benefit in patients treated with the cholesteryl ester transfer protein (CETP) inhibitor dalcetrapib. We believe that our analysis1 of the evacetrapib outcome trial provides a more precise and reliable estimate of any association between this SNP and cardiovascular outcomes in patients treated with CETP inhibitors. Our analysis had more cardiovascular events in patients treated with a CETP inhibitor with the AA genotype (n = 125) compared with the dalcetrapib analysis (n = 38).2 Estimates of relative risk based on only 38 events are statistically unstable and inherently low in reliability.